Nanoparticles (NPs) have an outstanding position in pharmaceutical, biological, and
medical disciplines. Polymeric NPs based on chitosan (CS) can act as excellent drug …

The blood-brain barrier (BBB) constitutes a microvascular network responsible for excluding
most drugs from the brain. Treatment of brain tumors is limited by the impermeability of the …

Since the first dendrimer was reported in 1978 by Fritz Vögtle, dendrimer research has
grown exponentially, from synthesis to application in the past four decades. The distinct …

Drug delivery to central nervous system (CNS) diseases is very challenging since the
presence of the innate blood–brain barrier (BBB) and the blood-cerebrospinal fluid barrier …

A drug's aqueous solubility is defined as the ability to dissolve in a particular solvent, and it
is currently a major hurdle in bringing new drug molecules to the market. According to some …

Glioblastoma multiforme (GBM) is abnormal cell proliferation of glial cells. GBM is the grade
IV glioma brain cancer which is life-threatening to many individuals affected by this cancer …

Today, dendrimers are the main nanoparticle applied to drug delivery systems. The
physicochemical characteristics of dendrimers and their versatility structural modification …

The poor pharmacokinetic characteristics of most anticancer drugs have limited their clinical
effectiveness. The application of nanoparticles as a novel drug delivery system has provided …

The treatment of central nervous system (CNS) malignancies, including brain cancers, is
limited by a number of obstructions, including the blood-brain barrier (BBB), the …

Glioblastoma (GB) stands out as the most prevalent and lethal form of brain cancer.
Although great efforts have been made by clinicians and researchers, no significant …